Perhaps you can list all the advantages you see that Cynata is missing out on right now at this stage of the CYP-001 product development by not filing for RMAT designation as early as when submitting the IND application (which would have been an option).
In other words, where do you see the advantages of RMAT for a drug such as CYP-001 in aGvHD at its current development stage exactly?
In your opinion, would you say Orphan Drug designation is/was more beneficial at the current stage of product development or are we missing out on an important incentive right now that RMAT would have provided us with?
Perhaps you can list all the advantages you see that Cynata is...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.010(6.45%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.5¢ | 15.5¢ | $35.20K | 219.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 50171 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 70000 | 2 |
View Market Depth
| Last trade - 13.33pm 27/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |